APA (7th ed.) Citation

BS, D., BJ, S., TC, N., EP, M., JL, S., RA, F., . . . MB, C. (2024). AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life. Molecular therapy. Methods & clinical development, 32(1), 101205. https://doi.org/10.1016/j.omtm.2024.101205

Chicago Style (17th ed.) Citation

BS, Doshi, Samelson-Jones BJ, Nichols TC, Merricks EP, Siner JL, French RA, Lee BJ, Arruda VR, and Callan MB. "AAV Gene Therapy in Companion Dogs with Severe Hemophilia: Real-world Long-term Data on Immunogenicity, Efficacy, and Quality of Life." Molecular Therapy. Methods & Clinical Development 32, no. 1 (2024): 101205. https://doi.org/10.1016/j.omtm.2024.101205.

MLA (9th ed.) Citation

BS, Doshi, et al. "AAV Gene Therapy in Companion Dogs with Severe Hemophilia: Real-world Long-term Data on Immunogenicity, Efficacy, and Quality of Life." Molecular Therapy. Methods & Clinical Development, vol. 32, no. 1, 2024, p. 101205, https://doi.org/10.1016/j.omtm.2024.101205.